Schering Acquires Levitra Rights From Bayer; Vytorin Launch Is Still Priority

Schering-Plough's acquisition of Bayer's primary care products in the U.S. will not distract the company from the launch of Vytorin, Schering CEO Fred Hassan told investors Sept. 13 at a Bear Stearns conference in New York